2026 Nobel Prize in Chemistry Announced: Two Scientists Unravel the Mystery of Life's Chirality, with Results Profoundly Impacting the Pharmaceutical Industry

French chemist Henri B. Kagan and Japanese chemist Kenso Soai have jointly won the 2026 Nobel Prize in Chemistry for discovering nonlinear effects and autocatalytic phenomena in asymmetric organic synthesis. Their research answers a core puzzle that has perplexed the chemistry community for more than a century: why life chooses only one mirror image of a molecule. The Royal Swedish Academy of Sciences said the two laureates' discoveries enabled chemists to drive reactions toward a single chiral direction, breaking the previous deadlock in which equal amounts of mirror-image molecules were always produced in the laboratory. Heiner Linke, chairman of the Nobel Committee for Chemistry, commented that the two "provided an answer to a century-old chemistry puzzle, and the chemical reactions they developed are breathtaking." The two will share the 12 million Swedish krona prize equally. This honor has direct practical significance for the pharmaceutical, fragrance and agrochemical industries. Any company involved in producing substances that interact with living organisms relies on the theoretical framework established by the two laureates the nonlinear effect discovered by Kagan has become a core tool for optimizing asymmetric synthesis and improving enantiomeric purity, while the autocatalytic reaction system constructed by Soai achieved for the first time in artificial chemistry a complete transformation from achiral to homochiral. A century-old puzzle: why does life have only "one hand" The chemical composition of living organisms is known as "homochiral" amino acids exist in two mirror-image forms, but cell proteins contain only one of them; the sugar molecules that make up DNA are the same. However, when chemists try to synthesize chiral molecules in the laboratory, the two mirror images always appear in equal proportions and are difficult to separate. Take the "thalidomide" scandal of the 1960s as an example. The sedative caused birth defects in thousands of babies, and subsequent research found that it was the mirror-image isomer of the drug's active molecule that caused the harm. How to obtain only the therapeutically effective mirror image during synthesis became a core issue in pharmaceutical chemistry. At the theoretical level, British physicist Charles Frank established a mathematical model as early as 1953, pointing out that if a reaction simultaneously satisfies the three conditions of chiral catalysis, nonlinear amplification and autocatalysis, homochirality can emerge spontaneously. But turning this model into chemical reality remained an unresolved case for decades afterward. Kagan: nonlinear effects break the linear assumption In 1986, Henri B. Kagan, then at Universit Paris-Sud in France, took a key step. At the time, researchers generally believed that there was a linear relationship between catalyst chirality and product chirality, that is, the more chiral catalyst input, the correspondingly higher the proportion of the corresponding mirror-image molecule in the product. Kagan questioned this assumption. He analyzed the structure of the catalyst in depth and believed that metal atoms in the reaction might simultaneously attract multiple chiral molecules, thereby forming three catalyst forms: "right-right," "left-right" and "left-left." The key point is that the catalytic efficiency of the "left-right" mixed catalyst is far lower than that of the other two, which means that when a small amount of enantiomer is mixed into the catalyst, its interference with the product's chiral ratio is far smaller than expected, and the asymmetry of the reaction is therefore amplified. Experimental results confirmed this inference: the relationship between the chiral ratio in the catalyst and the chiral ratio in the product is curved rather than linear, the so-called "nonlinear effect." In a paper published that year, Kagan described three asymmetric reactions exhibiting this effect, satisfying the second condition of Frank's model, and it quickly attracted widespread attention in the chemistry community. This discovery not only has theoretical value, but also gives chemists a practical tool: by judging whether a reaction has nonlinear characteristics, key information about the catalytic mechanism can be obtained, and synthesis conditions can then be optimized to obtain the target enantiomeric product with higher purity. Soai: the first complete transformation from achiral to homochiral It was inspired by Kagan's discovery that Kenso Soai began exploring asymmetric autocatalytic reactions. He noticed that in a reaction with a significant nonlinear effect, the catalyst structure was highly similar to the product structure, which gave rise to the idea of designing an autocatalytic asymmetric reaction. In 1995, Soai described in a paper the first reaction satisfying all of Frank's conditions: starting from 5-pyrimidyl alkanol containing a 2% excess of one enantiomer, after the reaction ended the excess of that enantiomer rose to 87%. This self-amplifying reaction was already very close to the theoretical target, but had not yet reached the 100% chiral purity of living organisms. After another eight years of exploration, Soai reported a landmark result in 2003: starting from achiral molecules, a single chirality could arise spontaneously through randomness alone. In the early stage of the reaction, both enantiomers were generated, but the tiny difference formed by chance was gradually amplified through the autocatalytic mechanism, and eventually one enantiomer could account for 99.99% of the product. When the experiment was repeated, which enantiomer "won" depended on the initial random event this closely simulated the possible mechanism of chiral selection at the origin of life, and was also the first time in human history that a complete transformation from achiral to homochiral was achieved in an artificial chemical system. Practical value for the pharmaceutical industry The research results of the two laureates have already had a profound impact on multiple industries. The nonlinear effect discovered by Kagan is now widely used in pharmaceutical chemistry, helping researchers optimize catalyst design and obtain target enantiomers with higher purity in drug synthesis, fundamentally reducing the risk of a repeat of an event like "thalidomide." Fragrance and flavor companies and agrochemical enterprises have also benefited from this theoretical framework. Although the Soai reaction itself is an artificial system and differs from the chemistry of life, it has inspired researchers worldwide to try to synthesize homochiral amino acids and sugars using similar principles, pushing research into the origin of life into a new stage. Henri B. Kagan, born in 1930 in Boulogne-Billancourt, France, received his doctorate from the Collge de France in 1960 and is now an emeritus professor at Universit Paris-Sud in France. Kenso Soai, born in 1950 in Hiroshima, Japan, received his doctorate from the University of Tokyo in 1979 and is now an emeritus professor at Tokyo University of Science. This article is reprinted from Wall Street Insights, author: Zhang Yaqi; GMTEight editor: Xu Wenqiang.